Hispanic/Latino patients have a higher incidence of gastric cancer and worse cancer-related outcomes as compared to patients of other backgrounds. Whether there is a molecular basis for these disparities is unknown, as very few Hispanic/Latino patients were included in previous studies. We performed a large, integrated genomic analysis of gastric cancer samples from Hispanic/Latino patients. Whole-exome sequencing (WES) and RNA sequencing were performed on 57 Hispanic/Latino gastric cancer patient samples. Germline analysis was conducted on 83 patients. Functional testing of CDH1 germline mutations was performed in Chinese hamster ovary cells. Tumors from Hispanic/Latino patients were significantly enriched for the genomically-stable subtype (as defined by The Cancer Genome Atlas), compared to Asians and Whites (65% vs 21% vs 20%, P < 0.001). Transcriptomic analysis identified molecular signatures that were prognostic. Of the 43 Hispanic/Latino patients with diffuse-type gastric cancer, 7 (16%) had germline mutations in CDH1. Mutation carriers were significantly younger than non-carriers (41 vs 50 years, P < 0.05). E-cadherin expression was reduced in 5 of 6 mutation carrier tumor samples available for analysis. In silico algorithms predicted 5 variants were deleterious. For the two variants that were predicted to be benign, we demonstrated that the mutations conferred increased migratory capability, suggesting pathogenicity. Hispanic/Latino gastric cancer patients possess unique genomic landscapes.
Introduction
Gastric cancer is the second-deadliest cancer worldwide, causing an estimated 834,000 deaths in 2016. 1 Hispanic/Latino patients have different clinicopathologic features than patients of other ethnicities and races. In the United States, Hispanics/Latinos have twice the incidence and mortality from gastric cancer compared to non-Hispanic Whites. 2 Hispanic/Latino gastric cancer patients also tend to be diagnosed at a younger age, with more advanced-stage disease, and with a higher proportion of diffuse-type cancers (DGC). [3] [4] [5] While environmental exposures and socioeconomic factors likely contribute to the observed clinicopathologic differences, ethnicity/race-associated differences in tumor biology may also be involved. For example, African-American breast cancer patients have higher rates of triple-negative cancers and a higher prevalence of TP53 mutations, as compared with White patients. 6, 7 Whether there is a molecular basis for observed outcome differences for gastric cancer patients of different ethnicities/races has been heretofore unanswerable as previous large gastric cancer genomic studies had included very few Hispanic/Latino patients. The TCGA has performed the largest published sequencing study of gastric adenocarcinoma and included only five Hispanic/Latino patients in its 443-patient cohort. 8 Other major sequencing efforts of gastric cancer originated in East Asia, including those by Ichikawa et al (207 patients) and Cristescu et al (300 patients); these studies also did not include any Hispanic/Latino patients. 9, 10 Given the known association between ethnicity/race and tumor biology, the underrepresentation of Hispanic/Latino patients in previously published studies have likely biased our current genomic understanding of gastric cancer. 11 To address this knowledge gap, we performed a large, integrated genomic analysis of samples from 83 Hispanic/Latino gastric cancer patients. Comparative analyses were performed using data from Asian and White patients previously published by The Cancer Genome Atlas (TCGA). 12 
Methods

Sample acquisition and processing
This study was approved by the University of Texas Southwestern Medical Center Institutional Review Board. All gastric adenocarcinoma patients who were self-reported as being of Hispanic/Latino ancestry were recruited to join the study. All enrolled patients provided written consent.
Blood samples were drawn and stored at -80ºC prior to nucleic acid extraction. Tumor and adjacent non-neoplastic gastric tissue were obtained from treatment-naïve subjects via endoscopic biopsies or gastric resections. The samples were stabilized immediately in RNAlater (Ambion) for at least 24 hours at 4ºC, then stored in liquid nitrogen until nucleic acid extraction.
A second set of adjacent tissue samples from both the tumor and non-neoplastic stomach were also obtained for pathologic examination to confirm the histology, and to provide a microscopic assessment of tumor cellularity and extent of tumor necrosis. These samples were evaluated by a board-certified pathologist with expertise in gastrointestinal malignancies (S.T.G.H.) No samples were excluded on the basis of tumor cellularity, consistent with the TCGA collection protocol. Samples with greater than 10% necrosis were excluded. For some samples, RNA was isolated with mirVana miRNA Isolation Kits (Ambion) and DNA was isolated with QuickGene DNA Tissue Kits (Kurabo). Other samples were processed using the AllPrep DNA/RNA kits (Qiagen) . Nucleic acid quality control was ensured with NanoDrop (Thermo Fisher) spectrophotometric quantitation and visualization on an agarose gel.
Generation of CDH1 mutants
Chinese hamster ovary (CHO) cells (ATCC, CCL-61) were maintained in F-12K medium (Gibco) with 10% fetal bovine serum supplementation. Wild-type human CDH1 on a pcDNA3 plasmid was obtained (hE-cadherin-pcDNA3, Addgene, 45769). Variants were generated using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs). Plasmid transfection was performed with Lipofectamine 3000 (Invitrogen). Selection was performed with G-418 (Sigma).
Sanger sequencing was performed to confirm sequences using the following primers (Genewiz): 
Patient and public involvement statement
Neither patients nor the public were involved in the design, conduct, reporting, or dissemination of our research.
Results
We performed WES and RNA-seq on tissue samples from 57 patients. Blood samples were also obtained from 52 of these patients and used as normal controls. For the five patients for whom blood samples were unavailable, we used non-neoplastic gastric tissue as controls.
We also performed WES on blood samples from an additional 26 patients (Table 1 and Supplementary Table 1 ). The mean coverage for WES was 267x for the 57 tumor samples, 209x for the five non-neoplastic gastric samples, and 67x for the 78 blood samples. For RNAseq, the average number of reads was 96.9 million, with an average mapping rate of 97.6% for the 57 tumors and 5 non-neoplastic gastric samples.
Consistent with previous reports, the median age at time of diagnosis for the 83-patient Hispanic/Latino patient cohort was younger than that for the 77 Asian and 172 White patients analyzed by the TCGA (52 years, vs 66 and 66 years, respectively, P < 0.0001, Supplementary   Fig. 1a ). To confirm that the Hispanic/Latino cohort's self-reported ancestry was unique from that of the TCGA Asian and White patients, we compared WES data from each of the three groups to reference data available through the Human Genome Diversity Project (HGDP). 13 Using principal component analysis, we found that the Hispanic/Latino cohort clustered independently from the Asian and White patients in the TCGA groups and were related most closely to the HGDP samples from Central and South America ( Fig. 1 and Supplementary Fig.   1b ).
Gastric Cancers in Hispanic/Latino Patients are Enriched for the Genomically-Stable Subtype
We next classified the 57 Hispanic/Latino gastric cancer samples into one of the four molecular subtypes established by the TCGA ( Supplementary Fig. 2a ). 12 We did not include African-Americans in this analysis, as there were only four African-American patients in the TCGA cohort. Tumors were first characterized based on Epstein-Barr virus (EBV) infection status, which was determined bioinformatically with PathoScope 2.0. 14 We found no EBV infections, whereas 10% of the TCGA cohort was EBV-positive. 12 Next, microsatellite instability (MSI) was assessed bioinformatically using MSISensor, which has previously demonstrated near-perfect concordance with the results of PCR or immunohistochemical analysis. 15, 16 Three of the 57 samples (5%) had MSIsensor scores of greater than 10, indicating microsatellite instability ( Supplementary Fig. 2b ). Accordingly, these three samples showed mutation burdens greater than 13 mutations per megabase (Mb), whereas the average mutation burden for the 54 non-MSI samples was 2.5 mutations per Mb.
The remaining samples underwent somatic copy number alteration (SCNA) analysis. 10 17 samples (30%) had high SCNA scores, which placed them into the CIN group, and 37 patients (65%) had low scores and were categorized as genomically stable (GS; Fig. 2a ). When compared to the Asian (20%) and White (21%) patients, Hispanic/Latinos had a significantly higher proportion of GS tumors (65%, P < 0.001; Fig. 2b ). There were no significant differences between Asian and White patients in the proportions of subtypes. CIN samples showed an average of 3.5 mutations per Mb, while GS tumors had 2.0 mutations per Mb. This is consistent with the TCGA data found on the Broad Firehose, which showed CIN and GS samples as In the TCGA analysis, the GS subtype was found to be enriched for tumors with diffusetype histology. 12 Accordingly, we found that of the 37 GS patients, 78% had diffuse-type, 16%
had intestinal-type, and 6% had mixed-type tumors. In contrast, the CIN cohort was comprised of 23.5% diffuse, 53% intestinal, and 23.5% mixed-type tumors (P < 0.001, Fig. 2a ).
Hispanic/Latino Gastric Cancers Recapitulate Key Genomic Features Identified by the TCGA
Although the Hispanic/Latino samples were significantly enriched for GS tumors, many defining genomic alterations previously identified by the TCGA were recapitulated in the current cohort. For example, the most common recurrent mutation in Hispanic/Latino gastric cancer samples was TP53. Other driver mutations commonly associated with gastric cancer, such as those in ARID1A and APC, were also found at a comparable frequencies (Fig 3a) . We also identified similar structural variations. The TCGA identified CLDN18-ARHGAP fusions in 15% of their GS-type tumors. These rearrangements lead to dysregulated RHOA signaling and loss of an epithelial phenotype. 12, 17 Using FusionCatcher and STAR-fusion to evaluate our RNA-seq data, we found that four (11%) tumors had this rearrangement ( Fig. 3b and Supplementary   Table 2 ). 18, 19 All four were GS and diffuse-type. We also observed that 76% of CIN tumors, which were enriched for intestinal-type histology, had amplifications in the 8q24.21 region. This was significantly higher than seen in GS samples, in which only 19% had this copy number abnormality ( Fig. 3b ; P < 0.001). We confirmed this finding in the TCGA cohort, which similarly showed an enrichment of this structural alteration in CIN samples. 12 The 8q24.21 region most notably carries the MYC oncogene, and other groups have noted that amplifications in this region are common in intestinal-type gastric cancers and are associated with worse outcomes in gastric cancer patients. [20] [21] [22] Finally, we identified five instances of KRAS amplification (12p12.1), all of which occurred in CIN patients, consistent with previous reports (Fig. 3b ). 23 
Gene Expression Profiling is Prognostic
To further interrogate the RNA-seq dataset, we selected top 50 most variably expressed genes and performed consensus clustering to identify patient subgroups. We found five clusters with distinct clinicopathologic profiles ( Fig. 4a , Supplementary Table 3 ). Patients in Clusters 2 and 3 tended to be younger, while Clusters 1 and 5 patients were older. Cluster 3 patients had tumors enriched for diffuse-type and GS tumors. We also found that the clustering provided significant prognostic capability. Cluster 1 patients had the shortest median survival at 7.7 months, whereas Cluster 4 patients had the longest survival, with median survival not reached. Set Enrichment Analysis 24 to identify pathways that were uniquely overexpressed in Cluster 1 and 4 tumors, we found that the upregulated pathways in Cluster 1 were involved in cell cycle regulation, cell growth, and epithelial-mesenchymal transition ( Fig. 4c ) while upregulated pathways in Cluster 4 were associated with an activated immune response ( Fig. 4d ).
Hispanic/Latino Patients with Diffuse-Type Tumors Have Frequent Germline CDH1 Mutations
We analyzed the WES data from either blood or non-neoplastic stomach from 83 patients and identified seven germline CDH1 mutations ( Fig. 5a , Table 2 ). All seven mutations were identified in patients with diffuse-type cancer (DGC; 16%) and were confirmed with Sanger sequencing ( Supplementary Fig. 4 , Supplementary Table 4 ). Two mutations were deletions and five were missense variants. In patients with DGC, the median age of mutation carriers was 41 years (range 36-54 years) while the median age of CDH1 wild-type patients was 50 years (range: 26-76 years; P < 0.05; Supplementary Table 1 ).
Pathogenic CDH1 germline mutations are known to cause hereditary DGC syndrome.
However, none of the germline mutation carriers in our Hispanic/Latino cohort had a family history of gastric cancer or lobular breast cancer, which is another manifestation of the mutation. 25 Previous reports have suggested that germline CDH1 mutations contribute to earlyonset gastric cancer in patients without family histories of cancer. 26 We performed a literature search to estimate the rate of germline CDH1 mutations in gastric cancer patients without family histories of gastric cancer, and identified four studies with relatively large cohorts. These included patients from Italy, 27 Canada, 28 China, 29 and Korea. 30 Out of a total of 600 patients, 350
had DGC, and approximately 12 germline mutations in the coding region of CDH1 were identified across 13 patients (3.7%), with 3 patients having deletions, and 10 having missense alterations ( Supplementary Table 4 ). 31, 32 Thus, the prevalence of germline CDH1 mutations in patients without a relevant family history was markedly higher in the Hispanic/Latino cohort than what has been reported in other ethnic/racial groups.
To determine whether the identified CDH1 mutations were pathogenic, we first checked the population frequency of these variants in the Genome Aggregation Database (https://gnomad.broadinstitute.org). All seven variants were found in less than 1% of both the general population and in the Latino cohort ( Table 2 ). We next queried the annotations of the five missense mutations in the ClinVar database. 33 Two were classified as benign (P15 and P20) while the rest were either of uncertain significance or had conflicting data (P30, P50 and P71). Next, we used SIFT and PolyPhen-2 to predict the variant functionality via a bioinformatic approach. 31, 32 Consistent with ClinVar annotation, P15 and P20 were predicted to be benign, but P30, P50, and P71 were projected to be pathogenic ( Table 2) . Of the six patients whose tissue samples were available for analysis, we performed immunohistochemistry for E-cadherin, and found that there was either decreased or complete loss of protein expression in five of the six patients, including in P15 and P20, who harbored putatively benign variants ( Supplementary   Fig. 5 ).
The variant found in P15, who was a 51 year-old man presenting with locally advanced disease, was a c.286 A>G transition that resulted in an I96V amino acid alteration. Patient 20, who was a 37 year-old woman presenting with metastatic disease, had an c.1849 G>A change that led to an A617T amino acid change. To test the effects of these variants in vitro, we generated plasmids carrying wild-type CDH1 or these two variants and transfected them into Chinese hamster ovary (CHO) cells, which do not express E-cadherin at baseline and has been used extensively by other groups to test CDH1 variant function [34] [35] [36] Sanger sequencing confirmed that the mutations were generated correctly. We found that both 286 A>G and 1849
G>A variants generated protein products that were normal in size and cellular localization ( Fig.   5b and Supplementary Fig. 6 ).
E-cadherin is involved in cell-cell adhesion and its loss can result in increased cellular migration. We performed scratch assays to test if 286 A>G or 1849 G>A affected the migratory ability of CHO cells. After 24 hours, parental CHO cells had completely covered the scratch. As expected, CHO cells expressing wild-type CDH1 led to significantly reduced cellular migration, with 68% of the wound distance remaining (P < 0.0001). However, 286 A>G expressing cells had only 54% (P < 0.01) and 1849 G>A expressing cells had only 53% (P < 0.001) of their wound distances remaining ( Fig. 5c and 5d ). Thus, both variants conferred significantly increased migratory capability.
Discussion
Hispanic/Latino patients experience significant gastric cancer outcome disparities.
Whether there is a molecular basis for these differences is unknown, as previous gastric cancer genomic studies included very few Hispanic/Latino patients. 9, 10, 12 To our knowledge, the only study to date that had included a large number of Hispanic/Latino patients was performed by Sahasrabudhe et al. 37 However, their analysis of 333 patients from Latin America was limited to targeted sequencing of only five genes involved in DNA repair.
In this study, we have performed a large, integrated analysis of Hispanic/Latino gastric cancer samples and compared our results to those from Asian and White patients samples published by the TCGA. We found that Hispanic/Latino gastric cancer patients had a high incidence of germline CDH1 mutations, and that their tumors were enriched for the GS molecular subtype. Our findings suggest that the lack of ethnic and racial diversity in samples analyzed by previous large-scale studies has likely biased our genomic understanding of gastric adenocarcinoma due to the overrepresentation of White and Asian patients. Previous studies in other cancer types also identified genomic differences based on ethnicity and race. Shi et al found that more than 50% of Asian non-small-cell lung adenocarcinoma patients had EGFR mutations, as compared to 20% of White patients. 39 In a study of African-American prostate cancer patients, Yamoah et al identified genomic biomarkers related to race that were highly prognostic. 40 Thus, having ethnically and racially representative study cohorts will enhance our understanding of fundamental disease biology and ensure that the efficacy of a selected treatment has been tested and confirmed for the patient's ethnic/racial background. 11, 38 Improved recruitment of underrepresented patient populations into future clinical and basic scientific studies should be mandatory.
The high rate of germline CDH1 mutations in our Hispanic/Latino DGC cohort is striking.
Of the seven mutations we identified, which represented 16% of the DGC patients, two had not been previously reported in ClinVar, three were annotated as uncertain or conflicting, and two were designated as benign. Thus, these variants would likely have been excluded as pathogenic. However, several lines of evidence suggest that these mutations have deleterious effects. First, previous studies have suggested that germline CDH1 mutations may contribute to early-onset DGC. 26 The variant carriers in our cohort had a median age of diagnosis of 41 years as compared to DGC patients with wild-type CDH1 who had a median age of 50 at diagnosis.
Second, E-cadherin protein expression was abnormal in five of the six tumors from CDH1 mutation carriers that were available for analysis. Third, in silico analysis predicted that three of the five missense mutations were pathogenic. Finally, functional modeling of the two missense variants annotated by ClinVar and predicted to be benign by both SIFT and PolyPhen2 demonstrated pathogenic cellular migration phenotype. Our findings speak to the limitations of the currently available tools to predict accurately the pathogenicity of a given variant. When 44 This suggests that revisions will be necessary to improve the sensitivity of guidelines for genetic testing to identify germline CDH1 carriers.
Previous analyses of early-onset gastric cancer have identified DGC as being associated with young age. 12, 45 The high rate of DGC in Hispanic/Latino patients is consistent with the younger age of diagnosis in this cohort. However, the molecular mechanism behind early-onset carcinogenesis in this subgroup is unknown. As discussed above, the high rate of germline CDH1 mutations in the Hispanic/Latino cohort may play a role. Previous studies in non-Hispanic/Latino cohorts showed that germline CDH1 mutations occurs in about 1-3% of non-familial gastric cancer patients. [27] [28] [29] [30] In addition, the TCGA reported only two CDH1 variants in 295 patients, and these were non-pathogenic. 12 Other factors unrelated to Lauren classification and GS subtype clearly affect the etiology of early-onset gastric cancer since three of four very young (<35 years old) patients in our cohort were in the CIN group, with two of them having intestinal-type cancers. This will be an important area for future study, as the incidence of gastric cancer is rising in the United States only amongst young patients and thus will likely disproportionately affect the Hispanic/Latino population and exacerbate gastric cancer outcome disparities. 46 While molecular classification systems proposed by the TCGA and others have provided new paradigms to study gastric cancers, the practical implications of this scheme for patient care remain elusive. Recently, Sohn et al. reported that the TCGA classification may provide both prognostic and predictive value in Korean patients. 47 They found that EBV tumors had the best outcomes and GS cancers had the worst. Recently, Kim et al showed that immunotherapy was effective mainly in EBV or MSI-type tumors, while CIN and GS cancers were generally resistant. 48 These findings have significant implications for the Hispanic/Latino cohort that we analyzed since 95% of the patients had either CIN or GS tumors. Using consensus clustering of RNA-seq data, we identified transcriptomic signatures that were prognostic and thus can aid in risk-stratification and treatment planning, as clinicians and patients contemplate the use and sequence of systemic therapies versus resection. Intriguingly, patients in the low-risk, favorable prognosis group had a gene signature suggestive of an activated immune response. Whether these patients will benefit from immune therapy is a possibility that should be tested.
Future studies of Hispanic/Latino populations will likely benefit from more refined definitions of ancestry mix. Hispanic and Latino groups encompass a geographically diverse population exhibiting significant genomic heterogeneity, due to the differential admixture of European, Indigenous American, and African populations. Previous studies have shown that ancestry proportions in Hispanic/Latino patients are associated with breast cancer incidence and outcomes. 49, 50 However, while our study cohort is derived from patients living in North Texas, the country of origin is heterogeneous, as suggested by the relatively broad cluster seen in the ancestry analysis.
In conclusion, while gastric cancer outcome disparities may result from a combination of environmental exposures and socioeconomic factors, inherent tumor biology is also an essential component. Our study analyzing a large cohort of Hispanic/Latino gastric cancer patients is an important step in addressing the outcome disparity that these patients face by providing a genomic context for their disease. We have found that gastric cancers arising in Hispanic/Latino patients exhibit significantly different genomic landscapes than those developing in Asian and White patients. There is an enrichment for GS tumors and a high rate of germline CDH1 mutations. Our findings should be considered in establishing guidelines for screening, genetic counseling, and treatment of Hispanic/Latino gastric cancer patients. were not present within the exome capture kit. The variants present in the intronic or intergenic regions were also excluded. In addition, the variants with low variant allele frequency (VAF) with low quality supporting reads were filtered out. Specifically, variants with VAF ≤ 0.2 were excluded if they had less than 3 high quality supporting reads. We defined high quality supporting read as a read containing the mutated nucleotide with a base quality score of 30 or higher at the mutation as well as alignment quality score of 50 or higher given by the aligner for the entire read.
Figure Legends
We used MutsigCV 1.4.115 to identify statistically significant recurrent somatic variations.
Full exome coverage data from MutsigCV website was used for this test. We used p value ≤ 0.05 as a cutoff for determining the significance of the recurrent mutations. We used GenVisR to generate a waterfall plot to visualize a pattern of recurrent variations in our cohort.16
Germline variations were identified with GATK Haplotypecaller and Strelka2. For GATK Haplotypecaller, we used recommended parameters and a variant recalibration stage with known variant databases.8-10,17 Because we focused on few specific cancer related genes, we used the union of the two germline mutation profiles to increase the sensitivity, then we manually inspected potential germline variations using IGV. 18 We also annotated the germline mutations using ANNOVAR, then selected a subset of mutations as potentially pathogenic by the following two criteria: 1) predicted as deleterious by SIFT19 and PolyPhen220 and 2) having a lower population frequency than 0.01 in gnomAD (https://gnomad.broadinstitute.org).
RNA sequencing and analysis
Libraries were made with TruSeq RNA Access Library kit (Illumina) and sequenced on HiSeq2500 (Illumina). We used FastQC, multiQC, and cutadapt for quality control and preprocessing. STAR v2.4.2a21 was used to align to a GRCh38_P01 reference with Genecode v22 gene annotation, then HTSeq 0.6.022 was used to generate counts for gene expression quantification. The same parameters used in the TCGA STAD project23 were used. DESeq224 was used to detect differentially expressed genes (DEG).
Consensus clustering using gene expression data was performed with
ConsensusClusterPlus. 25 The raw read counts were normalized using voom function in the limma package. Various k (number of clusters) from 2 to 20 were tested and k = 5 was selected based on Cophenetic correlation coefficient. We performed DEG analysis between the identified cluster 1 and clusters 2+3+4+5 and cluster 4 and clusters 1+2+3+5 using the DESeq2 and used GSEA for gene set enrichment analysis.26
FusionCatcher27 and STAR-Fusion28 were used with default parameters to detect gene fusion events. Fusion events identified by both algorithms were used for further analysis. Nonclipped raw FASTQ data and Ensembl v89 database29 were used as input and database, respectively. We visualized and manually inspected fused transcripts using supporting reads provided by the FusionCatcher and UCSC genome browser.30
Ancestry analysis
To identify each sample's inherited genetic characteristics, we performed an ancestry inference using Locating Ancestry from SEquence Reads (LASER) to analyze whole-exome sequencing data31 with default parameters. LASER constructs a reference principal component (PC) space with a set of reference individuals and places test samples into the PC space.
Ancestry of each sample can be inferred using distances in the PC space between the sample and the reference individuals. We downloaded and used a reference PC space data from the LASER website. The reference PC space was constructed with Human Genome Diversity Project32 data that contained 938 reference individuals from various ethnic groups. Then we calculated the first 4 PCs for each normal Hispanic/Latino sample and mapped it to the PC space.
Metagenomics for Epstein-Barr virus and Helicobacter pylori
We used PathoScope 2.033 with parameters (-b very-sensitive-local -m hi -k 100 -t 50 -L 101 -s 0.95 --adjreflen --reuse) to identify EBV infections using whole-exome and RNA sequencing data. We used the target microbial database (PathoDB) available from PathoScope 2.0 release, which was built from NCBI nr (non-redundant) nucleotide database as of 2014.34 To increase sensitivity, we performed the metagenomics analysis on both WES data and RNA-seq data.
Determining microsatellite instability
We used MSISensor35 with default parameters to predict the MSI status by calculating and comparing length distributions of microsatellites between tumor and normal sample. The
MSISensor calculated a score for each sample to determine the MSI status (e.g., higher scores indicate the sample is more likely to have MSI). If we have both of normal and blood samples for a patient, we did two tests and averaged the scores. Then we chose a cutoff 10 based on a pan-cancer MSI assessment study using the MSISensor.36
Determining somatic copy number alterations
We used CNVkit37 to perform copy number alteration (CNA) analysis for whole-exome sequencing data. Because our cohort was sequenced by two different vendors (DNA Link, Inc (San Diego) and Admera Health (New Jersey)) we divided the cohort into two batches based on the vendors and ran the CNVkit separately. For each batch, a pooled reference panel was built using normal samples, then somatic CNAs were called for each tumor sample. The CNA calling results were merged then GISTIC238 was used to identify recurrent CNA regions. CNA regions with |CNA value| < 0.1 were filtered out. We adopted a method from Ichikawa et al. 39 and (number of CNA regions > 41) was defined as a cutoff to stratify between genomically stable (GS) and chromosomal instability (CIN) subtypes.
